NR4A1 and breast carcinoma: Indeed, PIK3CA mutations are frequent in breast cancer, occurring in 28–47% of hormone receptor-positive breast cancers, 25% of HER2-positive breast cancers, and 8% of basal-like tumors (Stemke-Hale et al., 2008).